Who should not take cabergoline?

Although cabergoline is a commonly used and effective drug for hyperprolactinemia (HPRL), not all people are suitable for use. According to the instructions, this product is not suitable for inhibiting postpartum physiological lactation. That is to say, it is not recommended to use this drug to forcibly inhibit lactation due to simple milk secretion after normal delivery because there are certain risks. In addition, cabergoline is generally not recommended for pregnant or breastfeeding women because the drug may affect fetal development or have adverse effects on the baby through milk secretion. Therefore, female patients who are planning to become pregnant or are already pregnant should strictly follow the doctor's advice and weigh the pros and cons.

At the same time, some patients with underlying diseases also need to use it with caution. For example, cabergoline should be avoided or used with caution in patients with severe hepatic impairment, valvular heart disease, or the presence of fibrotic lesions (e.g., pulmonary fibrosis, pericardial fibrosis). Studies have shown that long-term use of high doses of these drugs may be associated with an increased risk of heart valve abnormalities, so for patients who require long-term medication, doctors often recommend regular echocardiograms to monitor heart health. In addition, this product should also be disabled for people who are allergic to ergot drugs.

In elderly patients and individuals with multiple chronic diseases, doctors often pay special attention to drug-drug interactions. For example, the concomitant use of certain antihypertensive drugs or psychotropic drugs may increase the risk of side effects. For patients with a tendency of hypotension, orthostatic hypotension may occur after taking cabergoline, so it is necessary to monitor blood pressure and adjust the dose appropriately under the guidance of a doctor.

In summary, although cabergoline is a highly effective drug, it has clear contraindications and usage restrictions. Patients must be evaluated by a doctor before use to ensure safety and effectiveness and avoid unnecessary risks.

Reference materials:https://www.drugs.com/mtm/cabergoline.html